FDA Approves TG Therapeutics Inc.'s MS Drug Briumvi
By Josh Beckerman
The U.S. Food and Drug Administration approved TG Therapeutics Inc.'s Briumvi, an antibody indicated for the treatment of relapsing forms of multiple sclerosis.
The drug is also known as ublituximab.
Before TG Therapeutics shares were halted Wednesday afternoon, the stock was up 9% to $8.51.
Write to Josh Beckerman at firstname.lastname@example.org
(END) Dow Jones Newswires
December 28, 2022 13:57 ET (18:57 GMT)Copyright (c) 2022 Dow Jones & Company, Inc.